{
}
Janux Therapeutics' shares soared nearly 75% after promising early-stage results for its prostate cancer drug, JANX007, which targets metastatic, castration-resistant prostate cancer. In a small trial, 16 patients showed significant reductions in prostate-specific antigens, with mild side effects reported. Analysts are optimistic about the drug's potential, raising share price targets as Janux prepares for further trials.
Matt Phipps
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Janux Therapeutics Shares Soar on Promising Prostate Cancer Drug Results
01:00 03.12.2024
Trending
Subcategory
Corporate News
Startups & Entrepreneurship
Economic Indicators
Global Trade Developments
Market Analysis and Predictions
Countries:
Companies:
Currencies:
People: